Table 3.
Descriptive statistics of efficacy assessments; intention-to-treat (ITT) population
| IRL790 | Placebo | |||||||
|---|---|---|---|---|---|---|---|---|
| Median | Mean (SD) | Median | Mean (SD) | |||||
| Baseline | Week 4 | Baseline | Week 4 | Baseline | Week 4 | Baseline | Week 4 | |
| UDysRS | 33 | 23* | 33 (12) | 22.6 (9)* | 35 | 36.5 | 39.5 (19) | 37.25 (14) |
| UPDRS 4 q 32–35 | 4 | 2 | 4.4 (2) | 2.1 (1) | 4.5 | 3.5 | 4.5 (1) | 3.5 (2) |
| PKG, dyskinesia | 6.8 | 3.9 | 5.6 (3) | 3.9 (3) | 6.7 | 4.7 | 11.8 (12) | 6.3 (6) |
| PKG, bradykinesia | 25.5 | 24.6 | 24.5 (5) | 26.2 (6) | 17.6 | 20.1 | 17.9 (4) | 19.9 (2) |
| UPDRS part 1 | 3 | 2 | 2.8 (2) | 2.8 (2) | 3 | 2 | 3.2 (1) | 3.0 (2) |
| UPDRS part 2 | 13 | 10 | 12 (5) | 10.4 (5) | 13 | 12 | 14.2 (8) | 13.8 (8) |
| UPDRS part 3 | 14 | 14 | 18.2 (10) | 15.7 (5) | 19 | 16 | 19.8 (7) | 15 (2) |
| UPDRS part 4 | 9 | 6 | 7.8 (2) | 6.3 (2) | 8.5 | 8 | 8.7 (2) | 7.5 (3) |
*P < 0.01; Wilcoxon signed rank sum test